Library Resources

REVIEW UroToday

Viewing 1-20 of 188 articles

Radium-223 in 2024 and Beyond: Resurrected and Disrupting the First-Line mCRPC Treatment Landscape

ESMO 2024 Quick Take Insights: Prostate Cancer

ESMO 2024 Quick Take Insights: A Focus on PEACE-3

ESMO 2024 Quick Take Insights: A Focus on ARANOTE

ESMO 2024 Quick Take Insights: A Focus on SPLASH

American Society of Clinical Oncology (ASCO) 2024 Bladder Cancer Updates

Radioligand Therapy for Metastatic Castrate-Resistant Prostate Cancer: Radium-223, 177Lu-PSMA-617, New Agents, and Novel Combinations

Gem/Doce in 2024: What is Next?

Indwelling Urinary Catheter Management of the Acute Patient: Quality Improvement Issue Brief

PARP Inhibitor Combination Therapy: Approved Treatments for Metastatic Castrate-Resistant Prostate Cancer Patients

PARP Inhibitor Therapy for Prostate Cancer Patients: Emerging Combinations

PARP Inhibitor Monotherapy for Prostate Cancer Patients

The Quickly Evolving Treatment Landscape of Metastatic Urothelial Carcinoma: A New Standard of Care in First-Line Systemic Therapy

Lessons Learned from COVID-19 in the Care of NMIBC Patients: Insights from the CISTO Investigators

CMS Releases Final Rule to Broaden Access to Health Data and Improve Prior Authorization

Cretostimogene Grenadenorepvec: At the CORE and Forming BONDs in High-Risk NMIBC and PIVOTing into Intermediate Risk NMIBC

Novel Targets and Treatment Developments in Metastatic Hormone Sensitive Prostate Cancer

Novel Treatment Targets in the Metastatic Castrate-Resistant Prostate Cancer Disease Space

The Current State of Treatment Implementation for mCRPC in North America

The Current State of Treatment Implementation for Metastatic Hormone Sensitive Prostate Cancer in North America

1
2
3
4
5
6
7
8
9
10